Switchability of gabapentin formulations : a randomized trial to assess bioequivalence between Neurontin and Gabasandoz on the individual subject level
- Author
- Griet Van Lancker (UGent) , Lucas Van Bortel (UGent) , Brant Delafontaine (UGent) , Koen Boussery (UGent) , Eleonora Swart, Abdel Chahbouni, Jan Van Bocxlaer (UGent) and Pieter Colin (UGent)
- Organization
Citation
Please use this url to cite or link to this publication: http://hdl.handle.net/1854/LU-8589911
- Chicago
- Van Lancker, Griet, Lucas Van Bortel, Brant Delafontaine, Koen Boussery, Eleonora Swart, Abdel Chahbouni, Jan Van Bocxlaer, and Pieter Colin. 2019. “Switchability of Gabapentin Formulations : a Randomized Trial to Assess Bioequivalence Between Neurontin and Gabasandoz on the Individual Subject Level.” Clinical Pharmacology & Therapeutics.
- APA
- Van Lancker, G., Van Bortel, L., Delafontaine, B., Boussery, K., Swart, E., Chahbouni, A., Van Bocxlaer, J., et al. (2019). Switchability of gabapentin formulations : a randomized trial to assess bioequivalence between Neurontin and Gabasandoz on the individual subject level. CLINICAL PHARMACOLOGY & THERAPEUTICS.
- Vancouver
- 1.Van Lancker G, Van Bortel L, Delafontaine B, Boussery K, Swart E, Chahbouni A, et al. Switchability of gabapentin formulations : a randomized trial to assess bioequivalence between Neurontin and Gabasandoz on the individual subject level. CLINICAL PHARMACOLOGY & THERAPEUTICS. 2019;
- MLA
- Van Lancker, Griet et al. “Switchability of Gabapentin Formulations : a Randomized Trial to Assess Bioequivalence Between Neurontin and Gabasandoz on the Individual Subject Level.” CLINICAL PHARMACOLOGY & THERAPEUTICS (2019): n. pag. Print.
@article{8589911,
author = {Van Lancker, Griet and Van Bortel, Lucas and Delafontaine, Brant and Boussery, Koen and Swart, Eleonora and Chahbouni, Abdel and Van Bocxlaer, Jan and Colin, Pieter},
issn = {0009-9236},
journal = {CLINICAL PHARMACOLOGY & THERAPEUTICS},
language = {eng},
title = {Switchability of gabapentin formulations : a randomized trial to assess bioequivalence between Neurontin and Gabasandoz on the individual subject level},
url = {http://dx.doi.org/10.1002/cpt.1353},
year = {2019},
}
- Altmetric
- View in Altmetric